About
Matisse Pharmaceuticals B.V. is a clinical-stage biopharmaceutical company developing therapies that neutralize extracellular cytotoxic histones, focusing on treating sepsis and septic shock with its lead product, isupartob sodium.
Explore Matisse Pharmaceuticals B.V.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.